Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
about
Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapyPhase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.Akt inhibitor MK-2206 enhances the effect of cisplatin in gastric cancer cells.Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.
P2860
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Phase 1b study of the mammalia ...... ts with advanced solid tumors.
@en
Phase 1b study of the mammalia ...... ts with advanced solid tumors.
@nl
type
label
Phase 1b study of the mammalia ...... ts with advanced solid tumors.
@en
Phase 1b study of the mammalia ...... ts with advanced solid tumors.
@nl
prefLabel
Phase 1b study of the mammalia ...... ts with advanced solid tumors.
@en
Phase 1b study of the mammalia ...... ts with advanced solid tumors.
@nl
P2093
P2860
P356
P1433
P1476
Phase 1b study of the mammalia ...... ts with advanced solid tumors.
@en
P2093
Catherine Sullivan
Daniel Zelterman
David P Tuck
Hari Deshpande
Indukala Doddamane
Kimberly Lezon-Geyda
Lyndsay N Harris
Masoud Azodi
Maysa M Abu-Khalaf
Megan A Baumgart
P2860
P304
P356
10.1002/CNCR.29254
P407
P577
2015-02-03T00:00:00Z